ALK/p80抗体;ALK/p80 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using ALK/p80 mouse mAb (green) and negative control (red).    

  
  

The ALK/p80 antibody is a critical tool in molecular pathology, primarily targeting the anaplastic lymphoma kinase (ALK) and its oncogenic variants, such as the p80 fusion protein. ALK, a receptor tyrosine kinase (RTK), is typically expressed in neural tissues and plays roles in development. Its pathological significance emerged with the discovery of ALK rearrangements, notably the t(2;5)(p23;q35) translocation, which fuses the ALK gene with nucleophosmin (NPM), generating the NPM-ALK fusion protein (p80). This constitutively active kinase drives oncogenic signaling (e.g., RAS/MAPK, PI3K/AKT) and is implicated in cancers like anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and subsets of non-small cell lung cancer (NSCLC).

The ALK/p80 antibody specifically detects the activated or overexpressed ALK protein, aiding in diagnostic immunohistochemistry (IHC) to identify ALK-driven malignancies. Its detection is pivotal for guiding targeted therapies, such as ALK inhibitors (e.g., crizotinib, alectinib), which improve outcomes in ALK-positive cancers. While p80 historically referred to the NPM-ALK fusion’s ~80 kDa molecular weight, the term now broadly encompasses ALK variants. ALK/p80 antibodies remain essential for both research and clinical practice, enabling precise tumor subtyping and therapeutic stratification. Their use underscores the importance of molecular diagnostics in personalized oncology.